A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS

Leukemia

Volumn 32, Issue 12, 2018, Pages 2648-2658

  Fenaux, Pierre ^a   Santini, Valeria ^b   Spiriti, Maria Antonietta Aloe ^c   Giagounidis, Aristoteles ^d   Schlag, Rudolf ^e   Radinoff, Atanas ^f   Gercheva Kyuchukova, Liana ^g   Anagnostopoulos, Achilles ^h   Oliva, Esther Natalie ⁱ   Symeonidis, Argiris ^j   Berger, Mathilde Hunault ^k   Götze, Katharina S ^l   Potamianou, Anna ^m   Haralampiev, Hari ⁿ   Wapenaar, Robert ^o   Milionis, Iordanis ^p   Platzbecker, Uwe ^q  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d MARIEN HOSPITAL DÜSSELDORF   (Germany)

^e Praxisklinik Würzburg   (Germany)

^f UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^g Varna Clinic of Haematology   (Bulgaria)

^h G PAPANICOLAOU HOSPITAL   (Greece)

ⁱ Cardiology Department   (Italy)

^j UNIVERSITY OF PATRAS   (Greece)

^k ANGERS UNIVERSITY HOSPITAL   (France)

^l TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^m JANSSEN CILAG GMBH   (Germany)

ⁿ EMEA Medical Affairs   (Bulgaria)

^o Biostatistics   (Netherlands)

^p Janssen Cilag Pharmaceutical SACI   (Greece)

^q UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFEPOETIN ALFA; HEMOGLOBIN; PLACEBO; ANTIANEMIC AGENT; ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL PAIN; ACUTE MYELOID LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; ATRIAL FIBRILLATION; BACKACHE; BRAIN ISCHEMIA; CACHEXIA; CAUSE OF DEATH; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE TRANSFUSION; ERYTHROID RESPONSE; ESOPHAGITIS; FATIGUE; FEMALE; FEVER; GASTRITIS; HUMAN; ILEITIS; KIDNEY FAILURE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METABOLIC DISORDER; MORTALITY; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NUTRITIONAL DISORDER; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHINOPHARYNGITIS; RISK FACTOR; SINUSITIS; SOFT TISSUE INFECTION; SUDDEN DEATH; SUPERFICIAL THROMBOPHLEBITIS; THROMBOCYTOPENIA; TIME TO FIRST TRANSFUSION; TIME TO TREATMENT; TOOTH ABSCESS; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; TREATMENT RESPONSE; UROSEPSIS; VOMITING; BLOOD TRANSFUSION; CLINICAL TRIAL; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; BLOOD TRANSFUSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 85048376902     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/s41375-018-0118-9     Document Type: Article

References (24)

1. Steensma DP. Are myelodysplastic syndromes ‘cancer’? Unexpected adverse consequences of linguistic ambiguity. Leuk Res. 2006;30:1227–33
2. Porta MGD, Malcovati L. Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. Haematologica. 2009;94:602–6
3. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111:86–93
4. Terpos E, Mougiou A, Kouraklis A, Chatzivassili A, Michalis E, Giannakoulas N, et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol. 2002;118:174–80
5. Giagounidis A, Mufti GJ, Mittelman M, Sanz G, Platzbecker U, Muus P, et al. Outcomes in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. Eur J Haematol. 2014;93:429–38
6. Tehranchi R. Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes. Med Oncol. 2006;23:37–49
7. Janssen-Cilag Ltd. Eprex 40,000 IU/ml solution—summary of product characteristics. 2016
8. Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, et al. Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:60–87
9. Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, Del Cañizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943–64
10. Santini V, Alessandrino PE, Angelucci E, Barosi G, Billio A, Di Maio M, et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res. 2010;34:1576–88
11. Killick SB, Carter C, Culligan D, Dalley C, Das-Gupta E, Drummond M, et al. Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol. 2014;164:503–25
12. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671–4
13. Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009;114:2393–2400
14. Jädersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellström-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood. 2005;106:803–11
15. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes, Ferrini PR, Grossi A, Vannucchi AM, Barosi G, Guarnone R, et al. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol. 1998;103:1070–4
16. Mantovani L, Lentini G, Hentschel B, Wickramanayake PD, Loeffler M, Diehl V, et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol. 2000;109:367–75
17. Spiriti MAA, Latagliata R, Niscola P, Cortelezzi A, Francesconi M, Ferrari D, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol. 2004;84:167–76
18. Platzbecker U, Symeonidis A, Oliva EN, Goede JS, Delforge M, Mayer J, et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia. 2017;31:1944–50. 10.1038/leu.2017.192
19. Hellström-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99:344–51
20. Spiriti MAA, Latagliata R, Niscola P, Cortelezzi A, Francesconi M, Ferrari D, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol. 2005;84:167–76
21. Mitjavila MT, Villeval JL, Cramer P, Henri A, Gasson J, Krystal G, et al. Effects of granulocyte-macrophage colony-stimulating factor and erythropoietin on leukemic erythroid colony formation in human early erythroblastic leukemias. Blood. 1987;70:965–73
22. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol. 1995;89:831–7
23. Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasova A, Vey N, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol. 2016;34:2988–96
24. Janssen Press Release. https://www.jnj.com/media-center/press-releases/eprex-epoetin-alfa-marketing-authorisation-extended-to-include-treatment-of-symptomatic-anaemia-in-patients-with-low-or-intermediate-1-risk-myelodysplastic-syndromes. Accessed 20 Apr 2017